GuruFocus Premium Membership

Professional Value Investing Tools at Affordable Prices

Try It 100% for 7 Days!

Holly LaFon
Holly LaFon
Articles (4655) 

Invesco European Growth Fund Comments on MorphoSys

September 05, 2013 | About:
MorphoSys (MOR) is a German biotechnology company with proprietary technology to develop human antibodies for specific diseases. Over the quarter, the company signed two licensing deals (with GlaxoSmithKline PLC and Celgene Corp., not held by the fund) for its proprietary compounds, providing outside validation for its technology as well as upfront cash and future royalty payments.

From Invesco European Fund's second quarter commentary 2013.

Rating: 4.0/5 (3 votes)


Please leave your comment:

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)